CIC
DFTX

Chase Investment Counsel’s Definium Therapeutics DFTX Stock Holding History

Chase Investment Counsel’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-692
Closed -$11K – 120
2022
Q1 		$11K Hold
692
– – ﹤0.01% 112
2021
Q4 		$14K Hold
692
– – 0.01% 115
2021
Q3 		$24K Buy
+692
New +$29.9K 0.01% 102

Other funds holding DFTX

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Chase Investment Counsel's DFTX Position: Q2 2022 in Review

Chase Investment Counsel sold out of Definium Therapeutics (DFTX) in Q2 2022, closing a stake of 692 shares — an estimated $11K sold.

Chase Investment Counsel first reported a position in DFTX in Q3 2021 and held it in 3 quarters. The position peaked at $24K in Q3 2021. 155 funds tracked by Wall St. Rank hold DFTX as of Q2 2022.

  • Chase Investment Counsel reported no remaining Definium Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Chase Investment Counsel sold 692 Definium Therapeutics shares in Q2 2022, an estimated $11K.
  • Chase Investment Counsel first reported a position in Definium Therapeutics in Q3 2021 and held it in 3 quarters.
  • Chase Investment Counsel's Definium Therapeutics position peaked at $24K in Q3 2021.
  • 155 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2022.

Based on Chase Investment Counsel's 13F filing for Q2 2022, filed 26 Jul 2022.